Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis

  • ODA Hitomi
    School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
  • MORI Akihiro
    School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
  • LEE Peter
    School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
  • SAEKI Kaori
    School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
  • ARAI Toshiro
    School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
  • SAKO Toshinori
    School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan

Bibliographic Information

Other Title
  • Internal Medicine : Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis

Search this article

Abstract

Sitagliptin is a dipeptidyl peptidase-4 inhibitor aimed at treating Type 2 diabetes mellitus (T2DM) and T1DM, by increasing blood levels of Glucagon-like peptide 1 (GLP-1) and insulin. The objective of this preliminary study is to characterize Sitagliptin’s ability for glycemic control, in healthy dogs under an oral glucose tolerance test (OGTT) environment. Overall, Sitagliptin did not result in any significant changes to temporal glucose and insulin concentrations. However, a ~55% increase in median total GLP-1 AUC0–120min was observed, as compared to baseline control in healthy dogs (n=5), thus indicating a similar mode of action of Sitagliptin between healthy dogs and humans. Future studies to validate the use of Sitagliptin with dogs suffering from insulin independent diabetes are warranted.

Journal

References(24)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top